



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

October 22, 1999

James R. Ervin
10508 Fernridge Ct.
El Paso, TX 79925-7835

Dear Mr. Ervin:

Thank you for writing to the Food and Drug Administration (FDA). Your letter was forwarded to the Center for Drug Evaluation and Research (CDER), one of the five centers within the FDA, for a response.

Thank you for your comments regarding Norplant. I will forward your letter to Dockets Management for processing. In addition, I will forward your letter to the division that reviews contraceptive products for their consideration.

I hope this information is helpful. Please do not hesitate to contact us again if we can be of further assistance.

Sincerely,

Vikki S. Kinsey
Executive Secretariat Team (HFD-006)
Center for Drug Evaluation and Research

96P-0215

A
C217 / ANS


FDA Commissioner David Kessler
Dockets Branch
FDA
Room 1-23
12420 Parklawn Drive
Rockville MD. 20857

RE: Docket 96P0215

Dear Commissioner Kessler,

We agree with the Population Research Institute. Norplant has damaged so many women in so many countries that it must be withdrawn from the market before it can damage any more. Please consider the Norplant petition with the greatest care. Wyeth Ayerst claims Norplant was tested on 55,000 women around the world, yet an estimated 50,000 are suing the company over the pain their product has caused. We may never know how many thousands of women around the world have had to suffer this drug delivery system's effects in silence because they lacked the legal rights and media outlets that American women have. We urge FDA to prevent more women around the world from needless victimization and take Norplant off the market.

Sincerely,

 Ellen M Ervin
James R. and Ellen M. Ervin
10508 Fernridge
El Paso, TX 79915